NEW YORK (Dow Jones) – U.S. pharmaceutical company Pfizer in the second quarter of 2010 once again benefited from the acquisition of Wyeth in October . But net valuation adjustments , integration and restructuring costs and interest costs for financing the acquisition slammed the book and came to gain some . (Picture : Pfizer )
Revenue climbed 58% to 17.33 billion USD, told the New York Pfizer Inc on Tuesday. Net income rose 9% to 2.48 billion USD. Adjusted to exclude restructuring and acquisition costs , earnings per share certificate rose by 29 % to $ 0.62 . Analysts had expected an average of $ 0.52 per share on revenue of 16.65 billion USD.
On her goals for the full year and for 2012 notes Pfizer. Net income per share is expected to reach 2010 unchanged from 0.95 to 1.10 USD and adjusted earnings per share $ 2.10 to $ 2.20 . The sales forecast is still 67 billion to 69 billion USD. For 2012, the company expects sales of between 65.2 billion and USD 67.7 billion and earnings per share of $ 1.58 to $ 1.73 or $ 2.25 adjusted to 2.35 USD.
DJG / sha / has / dok